Danaher falls 3.4% as investors parse modest core growth and Diagnostics softness despite a small guidance raise

Danaher Corporation (DHR) is down 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to investors digesting Danaher’s first-quarter update, where core revenue growth was modest and Diagnostics showed weakness, which may have outweighed the EPS beat and slight full-year EPS guidance increase. Another pressure point could be near-term uncertainty around capital allocation and integration expectations tied to the planned Masimo acquisition.

Details:

Danaher reported Q1 2026 revenue of about $6.0 billion (+3.5% year over year), while core revenue grew about 0.5%, signaling that a meaningful portion of the headline growth was driven by FX rather than underlying demand.

Segment results were mixed: Biotechnology posted strong core growth (about +7%), while Diagnostics declined on a core basis (about -4%), with management pointing to a lighter-than-typical Q1 respiratory season at Cepheid.

The company raised its full-year 2026 adjusted EPS outlook to $8.35–$8.55 (from $8.35–$8.50) and kept its full-year core revenue growth outlook at 3%–6%, which may have been seen as incremental rather than a major upside reset.

After the print, multiple Wall Street firms adjusted price targets, which can amplify a “sell the news” reaction even when results beat estimates.

Sources:

Danaher Investor Relations, MarketScreener, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DHR Insider Trading Activity

$DHR insiders have traded $DHR stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

MITCHELL P RALES (Chairman of Exec. Committee) has made 0 purchases and 6 sales selling 477,625 shares for an estimated $104,925,233.
BRIAN W ELLIS (Senior Vice President - GC) has made 0 purchases and 2 sales selling 21,776 shares for an estimated $4,773,863.
MATTHEW MCGREW (EVP & Chief Financial Officer) sold 16,172 shares for an estimated $3,470,831
GEORGEANN COUCHARA (SVP, Human Resources) has made 0 purchases and 2 sales selling 5,174 shares for an estimated $1,088,703.
TERI LIST sold 3,298 shares for an estimated $746,997
GREGORY M MILOSEVICH (Executive Vice President) sold 1,320 shares for an estimated $274,574

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$DHR Hedge Fund Activity

We have seen 981 institutional investors add shares of $DHR stock to their portfolio, and 1,035 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 15,127,962 shares (-75.1%) from their portfolio in Q4 2025, for an estimated $3,463,093,061
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 5,739,048 shares (-87.3%) from their portfolio in Q4 2025, for an estimated $1,313,782,868
FMR LLC added 4,359,214 shares (+28.8%) to their portfolio in Q4 2025, for an estimated $997,911,268
JPMORGAN CHASE & CO added 2,943,496 shares (+15.8%) to their portfolio in Q4 2025, for an estimated $673,825,104
VIKING GLOBAL INVESTORS LP removed 2,751,245 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $629,815,005
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,216,789 shares (+104.7%) to their portfolio in Q4 2025, for an estimated $507,467,337
AGF MANAGEMENT LTD added 1,963,129 shares (+inf%) to their portfolio in Q4 2025, for an estimated $449,399,490

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$DHR Government Contracts

We have seen $126,790,813 of award payments to $DHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

AB SCIEX SERVICE & MAINTENANCE AGREEMENT SUPPORT: $3,403,150
IN-VITRO REAGENTS - VISN 15, ORDERING PERIOD ONE: $2,952,609
MICROBIOLOGY REAGENTS & CONSUMABLES ADD CLAUSE 852.222-71 - COMPLIANCE WITH EXECUTIVE ORDER 13899: $2,353,640
MRSA REAGENTS: $1,992,719

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$DHR Congressional Stock Trading

Members of Congress have traded $DHR stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$DHR Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 01/29/2026
Jefferies issued a "Buy" rating on 01/29/2026
Goldman Sachs issued a "Buy" rating on 12/09/2025

To track analyst ratings and price targets for $DHR, check out Quiver Quantitative's $DHR forecast page.

$DHR Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 10 analysts offer price targets for $DHR in the last 6 months, with a median target of $242.5.

Here are some recent targets:

Subbu Nambi from Guggenheim set a target price of $235.0 on 04/22/2026
Catherine Schulte from Baird set a target price of $245.0 on 04/22/2026
Luke Sergott from Barclays set a target price of $230.0 on 04/14/2026
Evie Koslosky from Goldman Sachs set a target price of $230.0 on 04/13/2026
Vijay Kumar from Evercore ISI Group set a target price of $225.0 on 04/06/2026
Tycho Peterson from JP Morgan set a target price of $275.0 on 01/29/2026
Tycho Peterson from Jefferies set a target price of $265.0 on 01/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.